Novel Balloon-Assisted vs Direct Technique in EUS-Guided Gastroenterostomy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorChanghai Hospital

About this trial

Gastric outlet obstruction (GOO) refers to mechanical blockage at the pylorus or duodenum, most commonly caused by unresectable malignancies of the stomach, duodenum, or pancreas. At the time of diagnosis, the majority of lesions are no longer amenable to curative resection, and median survival ranges from only 11.3 to 21.3 weeks. Throughout the disease course, patients develop nausea, vomiting, and severe malnutrition, which markedly impair quality of life. Current strategies to relieve obstruction include endoscopic stent placement and surgical gastrojejunostomy; however, each is associated with distinct drawbacks, such as stent occlusion, prolonged operative times, and high complication rates.

Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is a minimally invasive technique in which a gastric-jejunal anastomosis is created under real-time EUS guidance, bypassing the obstructed segment and establishing a gastrojejunal shortcut. Compared with conventional surgery or endoscopic luminal stenting, EUS-GE offers reduced procedural trauma and lower recurrence rates, providing GOO patients with an additional, less-invasive therapeutic option.

Three main EUS-GE approaches have been described: the direct method, the balloon-assisted method, and the double-balloon-assisted method. The direct method requires large volumes of water instillation, posing hemodynamic risks in patients with cardiovascular or cerebrovascular disease. The double-balloon technique relies on expensive, specialized devices that have not yet been widely adopted. The conventional balloon-assisted method demands needle puncture of a partially inflated balloon, which compromises stability and can displace the target jejunum away from the gastric wall. All three techniques are technically demanding, limiting their broad clinical dissemination.

The investigators therefore designed and previously reported a dedicated single-balloon-assisted device specifically for EUS-GE. This novel system aims to shorten procedure time, reduce intraprocedural water volume, and enhance procedural safety. The present prospective, multicenter, randomized controlled trial was undertaken to validate the clinical efficacy and safety of this new single-balloon-assisted technique compared with the conventional direct water-injection method.

Eligibility criteria

Qualifiers

Age ranges from 18 to 80 years old

GOO patients caused by all reasons (including benign diseases such as ulcers or malignant tumors)

Not suitable for or cannot tolerate surgical operations and endoscopic intestinal stent implantation

There are no absolute contraindications for EUS-GE

Disqualifiers

Pregnant and lactating women

Unable or refused to provide informed consents

Patients with cognitive impairment, aphasia, mental disorders, or other conditions that may affect the patient's cooperation

Patients with endoscopic contraindications, anesthesia contraindications, digestive tract perforation or abdominal cavity infection

Trial design

Treatments tested in this trial

  • a novel balloon-assisted EUS-GE
  • direct EUS-GE

Treatment groups

272 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators